Press Release: Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive

HD
WC
PD
ET
SN
SC
LA
CY
LP

TD

Press Release: Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive

310 words
11 November 2014
21:30
Dow Jones Institutional News
DJDN
English
Copyright © 2014, Dow Jones & Company, Inc.

Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Nov 11, 2014) - Avita
Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) a regenerative medicine company specializing in the
treatment of wounds and skin defects, today announced that it has received an Australian R&D Tax
Incentive payment of $1.4M for the financial year ending 30 June 2014.

"The payment resulting from Australia's R&D Tax Incentive program provides an important additional
resource to innovate new advancements and explore additional applications for our proprietary
technology platform, ReCell(R) Spray-On Skin(R) ," commented Tim Rooney, Avita Medical's Interim
Chief Executive Officer.

ABOUT AVITA MEDICAL LIMITED

Avita Medical (http://www.avitamedical.com) develops and distributes regenerative products for the
treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary
tissue--culture, collection and application technology provides innovative treatment solutions derived
from a patient's own skin. The Company's lead product, ReCell(R) Spray--On Skin(R) , is used in a wide
variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE--marked for
Europe, TGA--registered in Australia, and SFDA--cleared in China. ReCell is not available for sale in the
United States; in the United States, ReCell is an investigational device limited by federal law to
investigational use. A Phase III FDA trial is in process.

FOR FURTHER INFORMATION:

Avita Medical Ltd.

Tim Rooney

Interim Chief Executive Officer/Chief Financial Officer

Phone: + 1 (818) 827-1695

Email: trooney@avitamedical.com

Avita Medical Ltd.

Lou Panaccio

Chairman

Phone: +61 (0) 8 9474 7738

Email: lpanaccio@avitamedical.com

(END) Dow Jones Newswires

November 11, 2014 05:30 ET (10:30 GMT)

Page152of286©2018Factiva,Inc.Allrightsreserved.CO
IN
NS

RE
PUB
AN

gchip : Avita Medical Limited
i257 : Pharmaceuticals | i951 : Health Care/Life Sciences
ccat : Corporate/Industrial News | neqac : Equities Asset Class News | npress : Press Releases | c23 :
Research/Development | ncat : Content Types | nfact : Factiva Filters
austr : Australia | apacz : Asia Pacific | ausnz : Australia/Oceania
Dow Jones & Company, Inc.
Document DJDN000020141111eabb001dv

Page153of286©2018Factiva,Inc.Allrightsreserved.